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NEOPLASIA
Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38
mitogen-activated protein kinase–dependent apoptosis in chronic
myelogenous leukemic cells
Gautam Bandyopadhyay, Tanusree Biswas, Keshab C. Roy, Swapan Mandal, Chhabinath Mandal, Bikas C. Pal, Samir Bhattacharya,
Srabanti Rakshit, Dilip K. Bhattacharya, Utpal Chaudhuri, Aditya Konar, and Santu Bandyopadhyay
We report that chlorogenic acid (Chl) in-
duces apoptosis of several Bcr-Abl–
positive chronic myelogenous leukemia
(CML) cell lines and primary cells from
CML patients in vitro and destroys Bcr-
Abl–positive K562 cells in vivo. In con-
trast, this compound has no effect on the
growth and viability of Bcr-Abl–negative
lymphocytic and myeloid cell lines and
primary CML cells. Sodium chlorogenate
(NaChl) exhibits 2-fold higher efficiency
in killing K562 cells compared with Chl.
NaChl also induces growth inhibition of
squamous cell carcinoma (HSC-2) and
salivary gland tumor cells (HSG), al-
though at 50-fold higher concentration.
NaChl inhibits autophosphorylation of
p210Bcr-Abl fusion protein rapidly. We dem-
onstrate that p38 phosphorylation is in-
creased in Bcr-Abl–positive cells after
treatment with NaChl and closely paral-
leled the inhibition of Bcr-Abl phosphory-
lation. NaChl did not increase phosphory-
lation of p38 in Bcr-Abl–negative cells
including HSC-2 and HSG that are respon-
sive to this compound, indicating that
p38 activation by NaChl is dependent on
Bcr-Abl kinase inhibition. Inhibition of
p38 activity by SB203580 significantly
reduced NaChl-induced apoptosis of K562
cells, whereas activation of p38 by aniso-
mycin augmented the apoptosis. These
findings indicate that inhibition of Bcr-
Abl kinase leading to activation of p38
mitogen-activated protein (MAP) kinase
may play an important role in the anti-
CML activity of Chl. (Blood. 2004;104:
2514-2522)
© 2004 by The American Society of Hematology
Introduction
Chronic myelogenous leukemia (CML) is a malignant clonal
disorder of hematopoietic stem cells leading to massive expan-
sion of myeloid lineage cells.1 The natural fate of CML is to
progress from a benign chronic phase into the fatal blast crisis
between approximately 3 and 5 years. Development of CML is
associated with a specific chromosomal translocation known as
the Philadelphia (Ph) chromosome that is detectable throughout
the course of the disease.2 Somatic mutation in Ph chromosome
originates from reciprocal translocation between the long arms
of chromosomes 9 and 22 and fuses Bcr with c-Abl genetic
sequences. Both the Bcr-Abl fusion proteins p210 and p185 can
cause CML or acute leukemia.3,4 The p210 form of Bcr-Abl is
seen in 95% of CML and in 20% of acute lymphocytic leukemia,
whereas the p185 form is identified in about 10% of acute
lymphocytic leukemia patients.5,6 The Bcr-Abl fusion proteins
are constitutively active non–receptor tyrosine kinases whose
activity is essential for transforming abilities.7 An almost
universal presence of Bcr-Abl in CML patients made this fusion
protein an attractive target for drug development. Bcr-Abl
inhibitors, STI571, adaphostin, and PD173955, are capable of
inducing a variable degree of apoptosis in human CML cells.8-10
The signal transduction pathways involved in mediating apopto-
sis by Bcr-Abl inhibitors are poorly defined. In the current study,
we describe a novel Bcr-Abl kinase inhibitor that triggers p38
mitogen-activated protein (MAP) kinase–dependent apoptosis
of Bcr-Abl–positive CML cells.
Materials and methods
Cells and reagents
The Ph chromosome CML cell line K562,11 Ph chromosome–negative
T-cell line Molt 4,12 myeloid cell lines U93713 and THP-1,14 and B-cell line
REH15 were purchased from the American Type Culture Collection
(Manassas, VA). Bcr-Abl–positive cell lines KU81216 and KCL2217 were
generously provided by Dr Carlo Gambacorti-Passerini (Instituto Nazionale
Tumori, Milan, Italy). Unless otherwise stated, all cells were cultured in
RPMI-1640 medium containing 10% fetal bovine serum and 100 units/mL
penicillin-streptomycin (Life Technologies, Grand Island, NY). Human oral
squamous cell carcinoma HSC-218 and human salivary gland tumor HSG18
were kindly provided by Prof Hiroshi Sakagami (Department of Dental
Pharmacology, Meikai University School of Dentistry, Sakado, Japan).
HSC-2 and HSG cell lines were maintained in Dulbecco modified Eagle
medium (Life Technologies) containing 10% fetal bovine serum and
antibiotics. Antibodies were purchased from the following suppliers:
Specific antibodies to c-Abl, Bcr, phospho–extracellular signal-related
kinase 1/2 (ERK1/2, Tyr-204), phospho-cellular protein kinase C
(p-cPKC) (Ser657), p-cPKCII/ (Ser660), phospho-Lyn (Tyr-508), Lyn,
phospho-HCK (Tyr-411), HCK, phospho-Fyn (Thr-12), Fyn, phospho–
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Janus kinase 1 (JAK1, Tyr-1022/1023), JAK1, phospho-JAK2 (Tyr-1007/
1008), JAK2, phospho-JAK3 (Tyr-980), and JAK3 were from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti–phospho-c-Abl (Tyr-245), anti-
ERK, and anti–cleaved caspase-3 were from Cell Signaling Technology
(Beverly, MA). Anti–caspase-3 that recognizes unprocessed pro–caspase-3
(32 kDa) and the subunit of the active caspase-3 (17 kDa), and anti–
phospho p38 (Thr 180/Tyr 182) were from BD Biosciences (Mountain
View, CA). Anti-p38 was purchased from Calbiochem (San Diego, CA).
The p38-specific inhibitor SB203580 and ERK1/2-specific inhibitor
PD98059 were from Calbiochem. Anisomycin and 12-O-tetradecanoylphor-
bol-13-acetate (TPA) were from Sigma Chemical (St Louis, MO). Matrigel
was obtained from BD Biosciences.
Purification of Chl from Piper betel leaves
The leaves of Piper betel (Piperaceae) were collected from different areas of West
Bengal, India. A voucher specimen has been deposited at the Department of
Medicinal Chemistry, Indian Institute of Chemical Biology, Kolkata. Fresh
leaves (5.3 kg) were extracted with distilled water in a mixture blender. The
extract was lyophilized to a semisolid mass (110 g), which was tested for killing
activity of K562 cells. A portion (10 g) of the extract was fractionated through
Sephadex LH-20 (Sigma Chemical) column chromatography using water,
water-methanol (1:1), and methanol as eluent to give 5 fractions. The active
fraction (0.24 g) was then subjected to preparative high-performance liquid
chromatography using -Bondapak column (Waters, Milford, MA) (19 300
mm) with solvent methanol–water–acetic acid (23:76:1) flow rate 12 mL/min
and the detection at 280 nm. A purified compound (5 mg) was isolated, which
showed the activity. The structure of the active compound was determined as
chlorogenic acid,19 C16H18O9, melting point 205°C to 206°C,D-33.25 (H2O). Its
identity was confirmed by comparing its physical data as well as its infrared (IR),
nuclear magnetic resonance (1HNMR), 13CNMR, and mass spectral data with
those of an authentic sample. Sodium chlorogenate (0.112 g) was prepared by the
reaction of chlorogenic acid (0.1 g) with sodium hydrogen carbonate (0.24 g) in
water (5 mL) followed by lyophilization of the resulting solution.
Clinical samples
Fresh peripheral blood samples were donated by 4 CML patients with stable
phase of the disease admitted to The Institute of Haematology and
Transfusion Medicine, Medical College, Kolkata before receiving any
treatment. Peripheral blood samples were collected with due approval from
the Human Ethics Committee of the respective institutes and all experi-
ments with human blood were conducted under an approved institutional
Human Ethics Committee protocol. Of the patients, 3 were Ph chromosome
positive and 1 was negative as determined by bone marrow cytogenetics
analysis. Ph chromosome–negative patient diagnosis of CML was con-
firmed by clinical and hematologic parameters20 (ie, huge splenomegaly,
sternal tenderness, anemia, leukocytosis, increased platelet count, and low
leukocyte alkaline phosphatase score). Bcr-Abl fusion protein was undetect-
able in this patient by Western blot analysis. Peripheral blood samples were
also collected from 3 healthy donors. Mononuclear cells were separated by
Ficoll/Hypaque density gradient centrifugation. Informed consent was
provided according to the Declaration of Helsinki.
Cell viability assays
K562, KU812, KCL22, THP-1, U937, REH, and Molt 4 cells (1  104)
in triplicate were incubated in 0.2 mL RPMI 1640–10% fetal calf serum
containing varying concentrations of Chl and NaChl. At the indicated
times, cells were collected by centrifugation (at 1000g for 5 minutes).
Cell viability was determined by the trypan blue exclusion assay. At
least 200 cells were examined in each sample. Viability of primary CML
cells was determined in the same way except that recombinant human
granulocyte-macrophage colony-stimulating factor (rhGM-CSF, 100
ng/mL; R & D Systems, Minneapolis, MN) was included. Because of
monolayer culture, treated and untreated HSC-2 and HSG cells were
detached from the wells by treatment with Cell Dissociation Solution
(Sigma Chemical) before counting.
Annexin V–PI binding and cell cycle assays
Cells were seeded at 1.5  105 cells/mL in the presence or absence of
NaChl (10 g/mL). Evaluation of apoptosis by the annexin V–propidium
iodide (PI) binding assay21 was performed using the annexin V–fluorescein
isothiocyanate (FITC) Apoptosis Detection Kit (BD Biosciences) according
to the supplier’s instructions. Apoptotic cells stained by annexin V are in the
lower-right quadrant. Late-stage apoptotic cells stained with both annexin V
and PI are in the upper-right quadrant. Apoptosis of K562 cells in the
presence or absence of MAP kinase inhibitors and activators was measured
as follows. Cells were pretreated with PD98059 (10 M), SB203580 (10
M), TPA (50 nM), or anisomycin (100 ng/mL) for 30 minutes; NaChl (10
g/mL) was added and incubated for 24 hours. Apoptosis was determined
by annexin V binding. For cell cycle analysis, cells were permeabilized and
stained with PI for DNA content analysis21 in a flow cytometer (BD LSR;
Becton Dickinson, San Jose, CA).
Confocal microscopy
Cells (K562 and Molt 4) were incubated with NaChl (10 g/mL) for 24
hours, stained with annexin V–Alexa568 (Boehringer Mannheim, Mann-
heim, Germany), seeded onto poly-L-lysine (Sigma Chemical)–coated
coverslips, and analyzed with a Leica TCS SP2 confocal laser scanning
microscope (DMIRB, 40 objective, Mannheim, Germany).
Immunoblotting
Cells (1.0  105 cells/mL) were incubated with medium alone or with
NaChl (10 g/mL) as indicated, collected by centrifugation, and boiled for
5 minutes in sodium dodecyl sulfate (SDS) buffer. Aliquots containing 80
g total cellular protein were separated by SDS–polyacrylamide gel
electrophoresis (PAGE) containing 10% polyacrylamide, transferred to
nitrocellulose, and probed with primary antibodies indicated in the figure
legends followed by horseradish peroxidase–coupled secondary antibodies.
In vitro immune-complex kinase assay
p210Bcr-Abl was immunoprecipitated from K562 cells using anti–c-Abl
antibody followed by incubation with protein A–Sepharose. Immune
complexes were washed, and autophosphorylation was measured in im-
mune complexes by resuspension in kinase buffer as described.22 NaChl at a
concentration of 50 ng/mL was preincubated with immune complexes for
30 minutes. Kinase reactions (autophosphorylation) were initiated by the
addition of 10 Ci (0.37 MBq) [32P]–adenosine triphosphate and were
incubated for 30 minutes at room temperature. Kinase reactions were
quenched by the addition of SDS sample buffer, and after heating at 100°C
for 5 minutes, phosphoproteins were resolved by SDS-PAGE and detected
by autoradiography. For determining the kinase activity of unfused Abl,
K562 cell lysates were first immunodepleted of Bcr-Abl with antibody
against Bcr followed by immunoprecipitation with antibody to c-Abl.
Flow cytometry
For intracellular staining, treated and untreated cells were immediately
fixed with 4% paraformaldehyde, permeabilized by fluorescence-activated
cell-sorter permeabilizing solution (BD Biosciences), and stored at 20°C
until all time points were collected to avoid day-to-day variation in staining.
At this stage, the fixed cells can be stored for at least one week before
staining. Before staining, permeabilized cells were treated with heat-
inactivated 2% normal goat serum to block nonspecific staining. After
blocking, cells were stained with indicated antibodies (0.2 g/105 cells) for
30 minutes. Isotype-matched control mouse antibodies and normal rabbit
sera were used as controls for specific mouse and rabbit antibodies,
respectively. After washing, cells were incubated with multiple adsorbed
FITC-conjugated secondary antibody (anti–mouse or anti–rabbit immuno-
globulin G, depending on the primary antibody), washed, and analyzed in a
flow cytometer (BD LSR, Becton Dickinson).
In vivo studies on K562 xenografts
K562 cells were suspended to 5  107 cells/mL in Matrigel (1 volume of
cells with 1 volume of cold Matrigel). Nude female mice 6 to 7 weeks of
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age (National Institute of Nutrition, Hyderabad and National Institute of
Immunology, New Delhi, India) were given injections of 0.2 mL of this
suspension. Animals were left untreated until K562 xenografts reached 200
to 300 mm3. NaChl at varying doses (25-150 mg/kg) was administered
intraperitoneally once a day for 10 days (5 mice per group). Phosphate-
buffered saline (PBS, 0.2 mL/mouse) was used as control. Animal studies
were conducted under an approved institutional Animal Care and Use
Committee protocol.
Statistical analysis
The statistical significance of variants between groups and within each
group of experiments with MAP kinase activators and inhibitors was
evaluated by one-way analysis of variance.
Results
NaChl reduces viability of Bcr-Abl–positive cells in vitro
and in vivo
In the process of searching for antileukemic activity from medici-
nal plants of India, chlorogenic acid (Chl) isolated from Piper betel
leaves was found to kill Bcr-Abl–positive K562 cells in vitro in a
dose-dependent manner without any appreciable effects on Bcr-Abl–
negative acute T-lymphoblastic leukemia cell line Molt 4 (Figure
1A). Interestingly, its sodium salt (NaChl) was twice as potent in
killing K562 cells (Figure 1A-B). To evaluate the specificity of the
findings, effects of NaChl on 2 additional Bcr-Abl–positive cell
lines (KU812, KCL22) and 3 additional Bcr-Abl–negative cell
lines (2 of myeloid origin and 1 of B-lymphocytic origin) were
investigated. Like K562, Bcr-Abl–positive cells KU812 and KCL22
were destroyed in vitro by NaChl in a dose-dependent manner,
although sensitivity of KCL22 to NaChl was slightly lower than
K562 or KU812 (Figure 1B). In contrast, Bcr-Abl–negative
myeloid (U937, THP-1) and B-lymphocytic cell line (REH) were
insensitive to NaChl (Figure 1B). Specific destruction of Bcr-Abl–
positive cell lines by NaChl prompted us to test this compound on
leukemic cells collected from Bcr-Abl–positive and –negative
CML patients. These primary CML cells were cultured in the
presence of rhGM-CSF and graded concentrations of NaChl.
NaChl reduced the viability of leukemic cells from all 3 Bcr-Abl–
positive CML patients in a time- and dose-dependent manner,
Figure 1. Effect of chlorogenic acid (Chl) and its
sodium salt (NaChl) on Bcr-Abl–positive and –nega-
tive cells. (A) K562 and Molt 4 cells were cultured in
medium (F) or with graded concentrations of Chl (10
g/mL, ‚; 25 g/mL, ) for indicated times, and viability
was determined by trypan blue dye exclusion test. (B)
Cells were cultured with NaChl (medium, F; 5 g/mL
NaChl, ‚; 10 g/mL NaChl, ). (C) Mononuclear cells
from 3 Bcr-Abl–positive and 1 Bcr-Abl–negative CML
patient were cultured in medium containing rhGM-CSF
() or with the same medium containing NaChl (5
g/mL, ‚; 10 g/mL, ). (D) Squamous cell carcinoma
(HSC-2) and salivary gland tumor cell line (HSG) were
cultured in the absence (F) or presence of varying
concentrations of NaChl (100 g/mL, ‚; 250 g/mL, Œ;
500 g/mL, f). (E) Indicated cells were cultured with
varying concentrations of NaChl for 4 days and viability
was determined. (F) K562 cells embedded in Matrigel
were staged in nude mice until tumors reached 200 to
300 mm3. PBS (F) and NaChl (25 mg/kg, ; 100 mg/kg,
‚; 150 mg/kg, E) were administered intraperitoneally
once a day for 10 days. (G) Morphologic changes of
K562 cells after 24 hours of treatment with 5.0 g/mL
NaChl (phase contrast micrographs,  400 using Olym-
pus CK40 microscope and Olympus SC35 Type 12
camera). Error bars denote standard deviation of 3
experiments.
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while viability of primary CML cells from a Bcr-Abl–negative
patient was unaffected (Figure 1C). Chl has been shown to inhibit
the growth of squamous cell carcinoma, HSC-2, and salivary gland
tumor cell line, HSG.18 We therefore investigated the effects of
NaChl on these oral tumor cell lines. In agreement with a previous
report,23 a high concentration of NaChl (	 250 g/mL) was
required to have detectable growth inhibitory effects on HSC-2 and
HSG cell lines (Figure 1D). In contrast, 50-fold less concentrations
of NaChl (5-10 g/mL) were sufficient to inhibit the growth of
K562 cells (Figure 1E). Administration of NaChl in nude mice
bearing K562 xenografts reduced the tumor growth in a dose-
dependent manner (Figure 1F).
NaChl induces apoptosis of Bcr-Abl–positive cells
Nuclear condensation, a sign of apoptosis, was evident in NaChl-
treated K562 cells (Figure 1G). We therefore investigated whether
NaChl-induced killing of Bcr-Abl–positive cells was due to
apoptosis. Apoptosis was determined by the appearance of phospha-
tidylserine on the external surface of the plasma membrane
(binding to annexin V, Figure 2A), appearance of apoptotic nuclei
(sub G0/G1 peak in DNA cell cycle analysis, Figure 2B), and
activation of caspase-3 (Figure 2C). Treatment with NaChl induced
apoptosis in K562 cells and leukemic cells of a Bcr-Abl–positive
CML patient, while it had no effect on either Molt 4 cells or
mononuclear cells of a healthy donor. Staining of K562 cell
membrane with annexin V and its absence in treated Molt 4 cells
support a specific apoptotic effect of NaChl (Figure 2D). In K562
cells, annexin V binding was detectable as early as 10 hours after
treatment with NaChl, while caspase-3 activation and appearance
of apoptotic nuclei were detectable after 48 hours (Figure 2E). This
could be explained by the fact that phosphatidylserine externaliza-
tion occurs very early in apoptosis, before any nuclear changes
have occurred.24
NaChl inhibits autophosphorylation of Bcr-Abl
NaChl induced apoptosis of Bcr-Abl–positive cells at much lower
concentrations (5-10 g/mL) than that observed with oral tumor
cell lines (	 250 g/mL). Blocking of Bcr-Abl tyrosine kinase
activity is known to result in apoptosis of Bcr-Abl–expressing
cells.8,9 We therefore evaluated the effects of NaChl on autophos-
phorylation of Bcr-Abl and unfused Abl (c-Abl) by Western blot.
Cells were treated with 10 g/mL NaChl for 30 minutes, harvested,
and lysed, and equal amounts of total proteins were subjected to
immunoblot analysis using antibodies to phospho-cAbl and cAbl.
Figure 2. NaChl induces apoptosis of Bcr-Abl–positive cells. (A) Flow cytometric analysis of annexin V binding. Cells were left untreated (NT) or were treated with NaChl
(10 g/mL) for 24 hours (T) before analysis. Values in the quadrants represent percent positive cells. (B) DNA cell cycle analysis after treatment of cells with NaChl (10 g/mL)
for 48 hours. Gates were set to assess the percentage of dead (
 2n DNA, M1), G0/G1 (2n DNA, M2), and S G2 M (	 2n DNA, M3). Bars denote boundaries of cell cycle
phases. (C) Immunoblot analysis of caspase-3 activation. Cells were treated with NaChl (10 g/mL) for 48 hours, harvested, and lysed by boiling in SDS sample buffer, and an
equivalent amount of lysates was separated by SDS-PAGE and electrotransferred. The filters were probed with anti–caspase-3 that recognizes both procaspase-3 (32 kDa)
and caspase-3 cleavage product (17 kDa). (D) Confocal fluorescence images of NaChl-treated (10 g/mL for 24 hours) K562 and Molt 4 cells after staining with annexin
V–Alexa. Molt 4 cells were used as negative control. (E) Time kinetics of apoptosis determined by different techniques. K562 cells were treated with NaChl (10 g/mL) for
indicated times and analyzed for annexin V binding, DNA cell cycle (apoptotic nuclei [Sub G0/G1 peak]), and cleaved caspase-3 by flow cytometry.
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NaChl inhibited autophosphorylation of both fused (Bcr-Abl) and
unfused Abl in Ph cells without affecting protein expression
(Figure 3A). Inhibition of Bcr-Abl phosphorylation by NaChl was
further confirmed in in vitro assays with immune-complexed
kinases. NaChl reduced autophosphorylation of Bcr-Abl and
unfused Abl (Figure 3B). An intracellular staining technique has
recently been reported to detect phosphorylated MAP kinases and
signal transducer and activator of transcription molecules.25,26 We
applied the same technique to substantiate the results of Western
blot. Intracellular phosphorylated Abl was demonstrated only in
K562 cells and mononuclear cells of Ph CML patients, and in
both cases NaChl treatment abolished the phosphorylation (Figure
3D). Abl protein was detectable in Ph and normal cells and
remained unaffected after NaChl treatment (10 g/mL) for 30
minutes (Figure 3E). Of note, unlike Western blot, phosphorylation
and protein expression of Bcr-Abl and c-Abl could not be
distinguished by flow cytometry assay. Anti–phospho-c-Abl anti-
body produced positive intracellular staining only in Bcr-Abl–
positive cells, whereas anti–c-Abl antibody stained both Bcr-Abl–
positive and –negative cells. This is in agreement with our Western
blot results. Therefore, reduction in phospho-c-Abl staining de-
tected by flow cytometry reflected reduction of Bcr-Abl phosphor-
ylation. Moreover, Bcr-Abl protein constitutes more than 70% of
total Abl protein in both K562 cells and Bcr-Abl–positive primary
CML cells (Western blot); thus drastic reduction in total Abl
expression detectable by flow cytometry indicates mainly the
reduction in Bcr-Abl expression. Our data also indicate that a flow
cytometry–based assay of phosphorylation status of proteins corre-
lates closely and reliably with that of conventional Western blot.
A much higher (50-fold) concentration of NaChl was re-
quired to inhibit the growth of HSC-2 and HSG cells compared
with that of Bcr-Abl–positive K562 cells. We therefore evalu-
ated the status of phosphorylated and unphosphorylated Bcr-Abl
( 210 kDa) and wild-type Abl ( 140 kDa) in these cells by
immunoblots with anti–phospho-c-Abl and anti–c-Abl antibod-
ies, respectively. In both cell lines (HSC-2, HSG), wild-type Abl
as well as its phosphorylated form in basal level were detectable,
while Bcr-Abl (phosphorylated or unphosphorylated) was unde-
tectable (Figure 3C).
NaChl treatment reduced the expression of phosphorylated Abl
in K562 cells in a dose- and time-dependent manner; maximum
inhibition (almost 100%) was achieved at 30 minutes at a
concentration of 10 g/mL (Figure 4A). Treatment with NaChl (10
g/mL) also resulted in a gradual decrease of total Abl protein after
3 hours (Figure 4B).
To determine whether the effects of NaChl are specific for fused
and unfused Abl or whether this agent also inhibits other known
kinases, several members of the Src-kinase family and JAK kinases
were evaluated in K562 cells by immunoblots with phosphospe-
cific antibodies. Neither phosphorylation nor protein expression of
Lyn, HCK, Fyn, JAK2, and JAK3 was affected by NaChl (Figure
4C). The phosphorylated form of JAK1 was undetectable in K562
cells, which continued to be undetectable after treatment with
NaChl. To investigate whether the anti–phospho-JAK1 antibody is
not working or whether K562 cells do not express the phosphory-
lated form of this kinase, the effect of NaChl on this kinase was
studied in Molt 4 cells known to express this kinase27 (Figure 4C).
Similarly, flow cytometry–based assays indicated that phosphoryla-
tion status and protein expression of PKC  and PKC II/ serine
kinases were unaffected by this compound (data not shown).
NaChl modulates MAP kinase pathways in K562 cells
We have demonstrated that NaChl is able to induce apoptosis of
Bcr-Abl–positive cells. We next examined the possible involve-
ment of the MAP kinases. The ERK1/2 MAP kinase was analyzed
because of its importance for growth and survival in many cell
types.28,29 The p38 MAP kinase was examined because of its
importance in the mediation of stress signals.30 Flow cytometric
analysis using phospho-specific antibodies against respective MAP
kinases was performed. These antibodies specifically recognize the
activated phosphorylated form of ERK1/231 and p38.32 Increased
phosphorylation of both p38 and ERK1/2 MAP kinases was
observed in K562 cells starting at 10 minutes after NaChl addition,
lasting only up to 30 minutes, and then declining to the basal level
at 3 hours (Figure 5A). Expression of ERK and p38 protein levels
remained unchanged throughout this incubation period (Figure
5B). NaChl induced enhanced phosphorylation of p38 and ERK1/2
Figure 3. NaChl inhibits Bcr-Abl and c-Abl autophos-
phorylation in Ph cells. (A) Immunoblot-based deter-
mination of Abl expression and phosphorylation status.
Cells were treated with NaChl (10 g/mL) for 30 minutes,
harvested, and lysed, and equivalent amount of lysates
were separated by SDS-PAGE and electrotransferred.
The filters were probed with anti–phospho-c-Abl (Tyr
245) (top panels) or anti–c-Abl antibody (middle panels).
-Actin was used as loading control (bottom panels). (B)
In vitro kinase assay of fused (Bcr-Abl) and unfused Abl
in the presence (T) or absence (NT) of NaChl (50 ng/mL,
30 minutes). (C) HSG and HSC-2 cells do not express
Bcr-Abl. Cells were harvested and lysed, and equivalent
amount of lysates were separated by SDS-PAGE and
electrotransferred. The filters were probed with indicated
antibodies. (D) Flow cytometric determination of Abl
phosphorylation status. Indicated cells were left un-
treated (NT) or incubated with NaChl (10 g/mL) for 30
minutes (T), fixed, permeabilized, and stained with rabbit
anti–phospho-c-Abl (Tyr 245) antibody. Dotted line indi-
cates staining with normal rabbit sera; solid line, staining
with anti–phospho-c-Abl antibody. (E) Flow cytometric
determination of intracellular Abl protein expression sta-
tus. Cells were fixed, permeabilized, and stained with
rabbit anti–c-Abl antibody. Dotted line indicates staining
with normal rabbit sera; solid line, staining with anti–c-Abl
antibody.
2518 BANDYOPADHYAY et al BLOOD, 15 OCTOBER 2004  VOLUME 104, NUMBER 8
MAP kinases in K562 cells by 30 minutes, followed by a decline at
3 hours that did not affect protein expression, which was confirmed
by immunoblot analysis (Figure 5C). The panel of Bcr-Abl–
positive and –negative cells was then evaluated for p38 activation
after NaChl treatment. NaChl induced p38 phosphorylation by 30
minutes, followed by a decline at 3 hours in all Bcr-Abl–positive
cells tested, while basal level of phosphorylated p38 remained
unchanged by NaChl in Bcr-Abl–negative cells including HSG and
HSC-2 cell lines (Figure 5D). Taken together, these data indicate
that the differences in detectable phospho-activities are not due to
changes in respective MAP kinase expression levels. The time
kinetics of enhanced phosphorylation of p38 and ERK1/2 in K562
cells by NaChl treatment closely coincided with reduced phosphor-
ylation of Bcr-Abl (Figures 4A and 5A,C). Thus, NaChl-induced
enhanced phosphorylation of p38 in Bcr-Abl–positive cells is
dependent on inhibition of Bcr-Abl phosphorylation.
The effects of specific MAP kinase inhibitors on NaChl action
To investigate the role of ERK and p38 pathways on NaChl-
induced apoptosis of K562 cells, we examined the effect of the
specific ERK inhibitor PD9805933-35 and p38 inhibitor
SB20358036-38 on p38 and ERK1/2 phosphorylation and apoptosis.
NaChl-induced enhanced phosphorylation of p38 in K562 cells
was partially reduced when cells were pretreated for 30 minutes
with 10 M SB203580 (Figure 6). ERK1/2 phosphorylation
remained more-or-less unchanged under the same experimental
condition (Figure 6). Similarly, NaChl-induced enhanced phosphor-
ylation of ERK1/2 in K562 cells was partially reduced after
pretreatment of cells with 10 M PD98059 without affecting
phosphorylation of p38 (Figure 6). Thus, inhibition of p38 is not
linked to ERK signaling and vice versa at the dose levels of
SB203580 and PD98059 tested. We next examined the effect of
specific ERK inhibitor PD98059 and p38 inhibitor SB203580 on
NaChl-induced apoptosis. K562 cells were incubated with 10
g/mL NaChl in the presence or absence of SB203580 or PD98059
(10 M each) for 24 hours. Apoptosis was measured by annexin V
binding. PD98059 further increased annexin V positivity of
NaChl-treated K562 cells (P 
 .01 vs NaChl alone), whereas
SB203580 inhibited (P 
 .01 vs NaChl) the apoptosis (Figure 7A).
These results indicate that activation of p38 but not ERK1/2 is
essential for NaChl-induced apoptosis of K562 cells and that
inhibition of ERK potentiates the apoptotic process. These findings
were further confirmed by treating K562 cells with NaChl in the
presence or absence of MAP kinase activators.
The effect of MAP kinase activators on NaChl action
Numerous studies have indicated that anisomycin and TPA are
strong activators of p3839,40 and ERK41-43 signaling pathways,
respectively. As demonstrated in previous experiments, if the
activation of p38 plays an important role in mediating apoptosis of
NaChl-treated K562 cells, then agents capable of stimulating p38
activity, when combined with NaChl treatment, should potentiate
apoptosis. This possibility was addressed by pretreating K562 cells
with anisomycin (100 ng/mL) for 30 minutes followed by treat-
ment with NaChl (10 g/mL) for 24 hours. Anisomycin further
increased p38 phosphorylation (Figure 6) and the induction of
apoptosis by NaChl (P 
 .01 vs NaChl) (Figure 7B). In contrast to
anisomycin, pretreatment of K562 cells with TPA (50 nM)
inhibited NaChl-induced apoptosis only marginally (Figure 7B).
These results indicate that p38 activation potentiates NaChl-
induced apoptosis of K562 cells, while ERK activation mediates
the opposite effect.
Discussion
In the present study, a Bcr-Abl kinase inhibitor was identified from
an herbal source. The compound was characterized to be chloro-
genic acid (Chl). Chl inhibits Bcr-Abl and c-Abl kinases and
induces apoptosis of Bcr-Abl–positive cells including Bcr-Abl–
positive primary leukemic cells of CML patients in vitro. The
compound was also effective in destroying K562 xenografts in
nude mice. Sodium chlorogenate (NaChl) appears 2 times more
potent than Chl, possibly because of higher solubility. NaChl has
no effect on some known kinases including several members of the
Src-kinase family (Lyn, HCK, Fyn), JAK-kinases (JAK2, JAK3),
and serine kinases (PKC, PKCII/). Chlorogenic acid has
diverse biologic activities including anti-HIV activity,44 antioxi-
dant activity,45 anticarcinogenic activity,46 modulating activity of
cytochrome P450-linked enzyme,47 antiallergic activity,48 and
apoptosis-inducing activity in human oral squamous cell carcinoma
Figure 4. NaChl inhibits phosphorylation of Abl in K562 cells in a time- and
dose-dependent manner without affecting Src-family kinases and JAK kinases.
(A) K562 cells were treated with varying concentrations of NaChl for 30 minutes (left
panel) or with 10 g/mL NaChl for varying time periods (right panel), fixed,
permeabilized, stained with anti–phospho-c-Abl (solid line) or normal rabbit sera
(filled histogram), and analyzed in a flow cytometer. (B) NaChl treatment reduces
Abl-protein expression in a time-dependent manner in K562 cells. Cells were treated
with NaChl (10 g/mL) for indicated times, fixed, permeabilized, and stained with
anti–c-Abl antibody (, cultured in medium; E, cultured in the presence of NaChl).
The level of expression is presented as mean fluorescence intensity (MFI). Data
represent mean  SD of 3 experiments. (C) Immunoblot-based determination of
protein expression and phosphorylation status of indicated kinases in indicated cells
before (NT) and after treatment for 30 minutes with NaChl (T). Experiments were
performed as mentioned in the legend of Figure 3A using indicated antibodies.
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and salivary gland tumor cell lines.18,23 Therefore, possible addi-
tional effects of Chl on cellular systems other than Bcr-Abl and
c-Abl kinases cannot be ruled out. Since Chl is known to inhibit
growth of squamous cell carcinoma and the salivary gland tumor
cell line, we evaluated whether these cells express Bcr-Abl kinase
and whether NaChl-induced growth inhibition of these cells is
associated with p38 activation. This was addressed to clarify
whether the effects of NaChl on Bcr-Abl–positive cells result from
inhibition of Bcr-Abl kinase or from a Bcr-Abl–independent
activation of p38 in these cells. In agreement with a previous
report,23 a 50-fold higher concentration of NaChl is required to
detect growth inhibition of these Bcr-Abl–negative cells compared
with that of Bcr-Abl–positive cells. Importantly, basal level of
phosphorylated p38 detectable in these Bcr-Abl–negative oral
tumor cells was not up-regulated by NaChl. To date, a number of
Bcr-Abl kinase inhibitors have been reported that are capable of
inducing apoptosis of Bcr-Abl–positive cells, but there is little
information on MAP kinase signaling pathways activated by these
Bcr-Abl inhibitors.8-10 We explored the role of MAP kinase signal
transduction system in NaChl-mediated apoptosis of Bcr-Abl–
positive K562 cells. Our data show that although ERK and p38
signal transduction pathways are activated rapidly in K562 cells
after NaChl treatment, activation of the p38 pathway, which is
dependent on inhibition of Bcr-Abl kinase, plays a critical role in
inducing apoptosis. This explanation has support from the follow-
ing observations: (a) NaChl induced enhanced phosphorylation of
both p38 and ERK MAP kinases in K562 cells very rapidly; (b)
NaChl-induced activation of p38 and ERK is dependent on
inhibition of Bcr-Abl phosphorylation. NaChl neither induces
apoptosis of Bcr-Abl–negative cells nor does it activate p38 in
these cells; (c) and inhibition of p38 signaling by specific inhibitor
inhibits NaChl-mediated apoptosis of K562 cells. In contrast,
inhibition of ERK signaling by a specific inhibitor potentiates
Figure 5. NaChl treatment enhances phosphorylation
of p38 and ERK1/2 MAP kinases in K562 cells. (A)
Cells were treated with NaChl (10 g/mL) for indicated
time periods, fixed, permeabilized, and stained with
isotype-matched control mouse monoclonal antibodies
(filled histogram) or anti–phospho-p38 and anti–phospho-
ERK1/2 monoclonal antibodies (solid line). Values within
histograms represent the specific MFI (after subtracting
the control values). (B) NaChl treatment does not alter
MAP kinase protein expression in K562 cells. Expression
of ERK () and p38 (E) is presented as mean fluores-
cence intensity (MFI). Data presented are mean  SD of
3 experiments. (C) Immunoblot-based determination of
p38 and ERK phosphorylation in K562 cells before and
after NaChl treatment. Cells were left untreated or treated
with NaChl (10 g/mL) for 30 minutes and 3 hours before
analysis. (D) NaChl treatment enhances p38 phosphory-
lation only in Bcr-Abl–positive cells. A panel of Bcr-Abl–
positive CML cell lines (KCL22, KU812), Bcr-Abl–
negative lymphoid (Molt 4, REH), myeloid (U937, THP-
1), squamous cell carcinoma (HSC-2), and salivary gland
tumor cell line (HSG) were left untreated or treated with
NaChl (500 g/mL for HSG and HSC-2 cells and 10
g/mL for other cells) for 30 minutes and 3 hours before
analysis by immunoblots with indicated antibodies.
Figure 6. Effects of MAP kinase inhibitors and activators on NaChl-induced
enhanced phosphorylation of p38 and ERK1/2 in K562 cells. Cells were
pretreated with inhibitors or activators of MAP kinases for 30 minutes as described in
“Materials and methods” before treatment with NaChl (10 g/mL) for an additional 30
minutes. Filled histograms indicate staining with isotype-matched control mouse
monoclonal antibodies. Solid lines indicate staining with anti–phospho p38 or
anti–phospho ERK1/2 monoclonal antibody. Values within the histograms represent
the specific MFI (after subtracting the respective control values).
Figure 7. Effects of MAP kinase inhibitors and activators on the NaChl-induced
apoptosis of K562 cells. (A) Cells were pretreated with the inhibitors for 30 minutes;
then NaChl (10 g/mL) was added and incubated for 24 hours. Apoptosis was
determined by flow cytometric assay based on annexin V binding. (B) Cells were
preincubated with the MAP kinase activators for 30 minutes before addition of NaChl,
followed by determination of apoptosis at 24 hours by annexin V binding. Data
represent mean  SD of 3 experiments. *P 
 .01 versus NaChl treatment alone. SB
indicates SB203580; PD, PD98059; Ani, anisomycin; and Con, control.
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apoptosis. (d) Further activation of p38 by p38 activator potentiates
NaChl-induced apoptosis of K562 cells, while more activation of
ERK mediates the opposite effect.
In K562 cells, a Bcr-Abl kinase inhibitor activated ERK, and
inhibition of the ERK pathway synergistically potentiated apopto-
sis induced by the Bcr-Abl kinase inhibitor.49 This is consistent
with our finding that ERK activation does not play a crucial role in
inducing apoptosis in these Bcr-Abl–positive cells. The general
consensus on ERK in regulating apoptosis is that activation of the
ERK pathway delivers a survival signal that counteracts proapop-
totic effects associated with JNK and p38 activation.29 Our data are
in agreement with this view as NaChl-induced apoptosis of K562
cells was inhibited by ERK activation, while inhibition of ERK
potentiated the apoptotic process.
p38 MAP kinase is primarily activated by various environmen-
tal stresses and has been suggested to play a critical role in
apoptosis.29,30 However, the role of p38 MAP kinase in inducing
apoptosis of CML cells by Bcr-Abl kinase inhibitors has not been
clearly documented. A recent report demonstrated the role of p38
MAP kinase in mediating growth inhibitory effects of interferon-
alpha in Bcr-Abl–expressing cells.50 We report that NaChl is a new
addition to the list of Bcr-Abl kinase inhibitors. We also demon-
strate that activation of p38 MAP kinase is a consequence of
Bcr-Abl kinase inhibition and plays a crucial role in mediating
apoptosis induced by a Bcr-Abl kinase inhibitor. How Bcr-Abl
kinase inhibition activates p38 MAP kinase is yet to be determined.
We propose that the p38 MAP kinase pathway contributes to the
apoptotic effect of other Bcr-Abl inhibitors that exhibit selective
growth inhibitory effects on Bcr-Abl–positive CML cells. In
agreement with our hypothesis, a recent report indicated that a
well-characterized Bcr-Abl kinase inhibitor STI571 induces apopto-
sis of Bcr-Abl–positive cells by activating the p38 MAP kinase.51 It
is possible that Bcr-Abl may exhibit constitutive negative regula-
tory effects on the activation of the growth inhibitory p38 MAP
kinase pathway. Inhibition of Bcr-Abl kinase activity by an
inhibitor, such as NaChl, may overcome the negative regulatory
effects of Bcr-Abl on p38 MAP kinase that lead to apoptosis.
Alternatively, inhibition of Bcr-Abl kinase may be recognized by
the cell as a stress that leads to activation of p38 and results in
induction of apoptosis.
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